Gout - Complete Guide to Gout!
Answers to your Gout Questions
SAN DIEGO, CA– – Ardea Biosciences, Inc. today announced that it has initiated the first of four planned Phase 3 clinical trials in its development program for lesinurad, the Company’s lead product candidate …
Continued here:
Ardea Biosciences Initiates Phase 3 Clinical Development Program for Lesinurad
Ardea Biosciences Inc. reported a larger third-quarter loss Friday as it continued to develop its gout drug candidates and its revenue decreased.
SAN DIEGO, CA–(Marketwire – Oct 19, 2011) – Ardea Biosciences, Inc. ( NASDAQ : RDEA ) today announced that additional data from the ongoing extension portion of a Phase 2b study (Study 203) of lesinurad, Ardea’s lead product candidate for the chronic treatment of gout, in combination with allopurinol in patients who did not achieve target serum urate (sUA) levels on allopurinol therapy alone …
See the original post:
Ardea Biosciences to Present Data From Gout Program at the 2011 ACR/ARHP Annual Scientific Meeting
Ardea Biosciences announced that it is in agreement with the FDA regarding the key features of the late-stage studies of gout candidate lesinurad.
Visit site:
Ardea Agrees with FDA on Gout Candidate
Shares of Ardea Biosciences Inc. rose Wednesday after the company said it reached an agreement with regulators about late-stage clinical trials of its gout drug candidate lesinurad.
We are upgrading Ardea Biosciences Inc. to Outperform from Neutral due to the promise shown by its lead pipeline candidate lesinurad, which is being developed to treat hyperuricemia and gout.
More here:
RDEA Upped to Outperform
SAN DIEGO, April 25, 2011 /PRNewswire/ — Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional data from its completed Phase 2b study (Study 203) evaluating lesinurad in combination with allopurinol in gout patients not adequately responding to allopurinol alone will be presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism …
We are maintaining our Neutral recommendation on Ardea Biosciences Inc. with a target price of $29.00.
Original post:
Ardea Biosciences in Neutral Lane
SAN DIEGO, March 11, 2011 /PRNewswire/ — Ardea Biosciences, Inc.
